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ABSTRACT	Epileptic	encephalopathies	(EEs)	are	the	most	clinically	important	group	of	severe	early-onset	epilepsies.	Next-generation	sequencing	has	highlighted	the	important	contribution	of	de	novo	mutations	to	the	genetic	architecture	of	EEs	in	addition	to	their	underlying	genetic	heterogeneity.	Our	previous	whole-exome	sequencing	study	of	264	parent-child	trios	revealed	more	than	290	candidate	genes	in	which	only	a	single	individual	had	a	de	novo	variant.	We	sought	to	identify	additional	pathogenic	variants	in	a	subset	(n=27)	of	these	genes	via	targeted	sequencing	in	an	unsolved	cohort	of	531	individuals	with	a	diverse	range	of	EEs.	We	report	17	individuals	with	pathogenic	variants	in	7	of	the	27	genes,	defining	a	genetic	etiology	in	3.2%	of	this	unsolved	cohort.	Our	results	provide	definitive	evidence	that	de	novo	mutations	in	SLC1A2,	CACNA1A	cause	specific	EEs	and	expand	the	compendium	of	clinically	relevant	genotypes	for	GABRB3.	We	also	identified	EEs	caused	by	genetic	variants	in	ALG13,	DNM1,	and	GNAO1	and	report	a	novel	mutation	in	IQSEC2.	Notably,	recurrent	mutations	accounted	for	7/17	of	the	pathogenic	variants	identified.	As	a	result	of	high-depth	coverage,	parental	mosaicism	was	identified	in	2	out	of	14	cases	tested	with	mutant	allelic	fractions	of	5-6%	in	the	unaffected	parents,	carrying	significant	reproductive	counseling	implications.	These	results	confirm	that	dysregulation	in	diverse	cellular	neuronal	pathways	causes	EEs	and	will	inform	the	diagnosis	and	management	of	individuals	with	these	devastating	disorders.	
Epi4K	Consortium	
	
2	
2	
	
INTRODUCTION	Epileptic	encephalopathies	(EEs)	frequently	begin	in	infancy	or	childhood	and	often	carry	a	poor	prognosis.	They	are	typically	characterized	by	multiple	seizure	types	and	abundant	epileptiform	activity	and	are	associated	with	developmental	delay	or	regression.	Genetic	studies	in	recent	years	have	established	that	de	novo	mutations	are	responsible	for	many	EE	phenotypes.	These	studies	have	also	highlighted	the	marked	genetic	heterogeneity	of	the	EEs,	emphasizing	the	value	of	sequencing	large	cohorts	to	identify	multiple	individuals	with	mutations	in	the	same	gene	to	establish	a	specific	gene’s	role	in	disease	causation.	Identification	of	multiple	individuals	affected	by	a	novel	disease	gene	allows	us	to	define	the	phenotypic	spectrum	of	that	disease	and	enables	recognition	of	co-morbidities,	prognosis	and	therapeutic	response.			Our	initial	whole-exome	sequencing	(WES)	study	of	264	parent-child	trios	focused	on	the	specific	EEs	of	infantile	spasms	(IS)	and	Lennox-Gastaut	syndrome	and	revealed	329	de	novo	variants	in	305	genes	1.	While	19	individuals	had	de	novo	mutations	in	previously	described	epilepsy	genes,	we	also	identified	a	statistically	significant	enrichment	of	mutations	in	GABRB3	(MIM:	137192)	and	ALG13	(MIM:	300776),	establishing	their	role	in	the	etiology	of	EEs	1.	Similarly,	DNM1	(MIM:	602377)	was	confirmed	as	an	EE	gene	in	our	subsequent	study	2.	For	over	290	genes,	a	de	novo	variant	was	identified	in	only	a	single	individual	with	insufficient	evidence	to	establish	association	with	disease	causation.	Identifying	a	significant	enrichment	of	cases	with	de	novo	variants	in	an	individual	gene	is	required	to	establish	that	gene’s	role	in	EEs,	ideally	in	combination	with	functional	validation	to	support	pathogenicity.			In	this	study,	we	employ	massively	parallel	targeted	sequencing	of	27	candidate	and	recently	described	EE	genes	in	a	large	cohort	of	531	individuals	with	a	range	of	EEs.	We	hypothesized	that	if	the	genes	in	which	a	de	novo	variant	in	the	original	study	was	identified	were	causative,	then	we	may	identify	additional	de	novo	variants	in	a	
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large	cohort	of	individuals	with	EE.	The	identification	of	an	enrichment	of	cases	with	the	same	genetic	etiology	would	confirm	the	role	of	a	specific	gene	in	causing	EE.	We	have	identified	individuals	with	a	de	novo	mutation	in	7	of	the	27	genes,	including	several	recurrent	mutations.	In	particular,	we	define	a	new	entity	of	SLC1A2	encephalopathy	and	highlight	its	importance	as	a	novel	glutamatergic	gene	for	EE.	We	also	emphasize	the	emerging	importance	and	diagnostic	value	of	CACNA1A	(MIM:	601011)	and	GABRB3	as	recurring	genes	causing	EEs.			
METHODS	
	
Gene	selection	for	targeted	sequencing	
	We	used	various	selection	criteria	and	expert	panel	review	to	select	~10%	of	the	290	genes	in	which	at	least	a	single	de	novo	variant	was	identified	in	the	original	Epi4K	cohort1	for	targeted	sequencing.	Selection	criteria	included:	a	gene	in	which	more	than	one	proband	in	the	original	study	had	a	de	novo	variant	(ALG13,	GABRB3,	
DNM1,	HDAC4);	a	gene	recently	described	as	causing	EE	(GNAO1);	gene	or	a	closely	related	gene	family	member	in	which	mutations	cause	epilepsy	or	related	disease	(CACNA1A,	GABRB1,	GRIN1,	MTOR,	PIK3AP1,	SLC1A2,	IQSEC2,	SLC35A2);	gene	predicted	to	have	protein-protein	interaction	with	a	known	epilepsy	gene	(HNRNPH1,	NEDD4L);	genomic	location	is	in	an	epilepsy-related	CNV	(YWHAG);	or	intolerance	to	functional	variation	using	the	residual	variation	intolerance	score	(RVIS)3	<25%	and	biological	plausibility	based	on	predicted	protein	function	(DNAJC6,	EMILIN3,	TRIM32,	RALGAPB,	VSP37A,	EPHB1,	NFASC,	PLXNA1,	SMURF1,	
THOC2,	TRIM32,	ZFHX3).			
Cohort	The	cohort	comprised	531	individuals	with	EEs	of	unknown	cause.	Most	of	these	individuals	had	been	tested	for	mutations	of	known	and	novel	candidate	genes	as	well	as	pathogenic	copy	number	variants	5-8,	so	the	cohort	represented	a	highly	selected	group	of	individuals	without	mutations	of	known	epilepsy	genes.	Detailed	phenotypic	characterization	was	performed	using	a	validated	seizure	questionnaire	
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9	together	with	review	of	medical	records,	EEG,	imaging	and	investigation	results.	Each	individual	underwent	phenotypic	analysis	and	was	classified	into	a	specific	epilepsy	syndrome	where	possible	10.			All	individuals,	or	their	parents	or	legal	guardians	in	the	case	of	minors	or	those	with	intellectual	disability,	gave	consent	for	participation	in	the	study.	The	study	was	approved	by	the	Human	Research	Ethics	Committee	of	Austin	Health,	Melbourne,	Australia	and	by	the	Institutional	Review	Board	at	the	University	of	Washington.			
Molecular	inversion	probe	design	and	library	preparation	
	Molecular	inversion	probes	(MIPs)	were	designed	as	previously	described	5	to	capture	the	coding	exons	plus	a	minimum	of	5	base	pairs	of	flanking	sequence	of	intronic/exonic	boundaries	in	each	of	the	27	genes.	Hybridization	and	amplification	was	performed	as	previously	described	5;	6;	8.		
	
Variant	calling	Libraries	were	sequenced	on	an	Illumina	HiSeq	following	the	manufacturer’s	instructions	to	generate	100	base	pair	paired-end	reads.	Raw	reads	were	mapped	to	the	human	genome	(GRCh37/hg19)	using	the	Burrows-Wheeler	Aligner	(BWA	v0.7.8)	and	variant	calling	was	performed	by	the	Genome	Analysis	Toolkit	(GATK	v3.1.1).	Duplicate	reads	were	marked	using	the	Picard	toolkit	(v.1.113).	SeattleSeq	(v137)	was	used	for	annotating	variants.	Only	variants	that	were	predicted	to	affect	protein	sequence	(missense,	nonsense,	frameshift,	or	splice	variants)	were	assayed	further.	CADD,	PolyPhen	and	GERP	scores	were	evaluated,	but	no	variants	were	excluded	due	to	in	silico	predictions.	Either	a	second	independent	MIP	capture	or	Sanger	sequencing	was	used	to	validate	and	test	segregation	of	variants	of	interest.	A	read-depth	of	50X	was	required	for	accurate	variant	calling.			
Criteria	for	pathogenicity	
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Variants	in	recently	identified	EE	genes	were	considered	pathogenic	if	they	arose	de	
novo	(or	from	a	somatic	mosaic	parent)	and	had	never	been	observed	in	the	publically	available	control	datasets	(ExAC	v0.3,	ESP6500,	1000	Genomes).	For	novel	genes,	the	number	of	de	novo	changes	observed	versus	predicted	was	assessed	to	determine	if	it	reached	statistical	significance	on	a	per-gene	basis	11.			In	cases	where	the	inheritance	was	not	known	because	of	the	lack	of	availability	of	parental	DNA	in	an	established	EE	gene,	the	significance	of	a	variant	was	based	on	whether	it	was	a	recurrent	mutation	or	convergent	information	provided	by	the	in	
silico	tools	CADD,	PolyPhen-2	and	GERP.	The	in	silico	tools	had	to	be	in	agreement	(CADD	>25,	PolyPhen-2	>0.9	and	GERP	>5)	to	classify	a	variant	as	‘likely	pathogenic’.	We	took	a	more	conservative	approach	to	novel	variants	with	limited	inheritance	information	for	genes	not	yet	established	as	causative	and	classified	these	as	variants	of	unknown	significance	regardless	of	in	silico	predictions.	Microsatellite	markers	were	used	to	test	the	relatedness	within	families	in	which	the	proband	had	a	‘de	novo’	mutation	and	to	rule	out,	when	possible,	sample	duplication	in	the	case	of	recurrent	mutations	(n=5/7	recurrent	mutations	tested).	For	one	inherited	GABRB3	variant	(NM_000814.4:c.470C>T[p.Thr157Met]),	review	of	the	pedigree	showed	that	the	variant	segregated	in	a	family	with	genetic	epilepsy	and	febrile	seizures	plus	(GEFS+).		
Statistical	Analysis	Mutation	enrichment	was	assayed	in	the	new	EE	genes	SLC1A2	and	CACNA1A	using	denovolyzeR	11.	Briefly,	using	weighted	per-gene	mutation	rates,	the	number	of	expected	de	novo	mutations	in	our	cohort	of	531	individuals	was	calculated	11.	The	probability	of	observing	greater	than	or	equal	de	novo	missense	mutations	than	those	expected	by	chance	was	calculated	using	denovolyzeR	correcting	for	27	genes	examined.	
	
	
RESULTS		
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We	sequenced	27	candidate	or	newly	described	EE	genes	in	a	cohort	of	531	individuals	with	unsolved	EE	representing	a	wide	range	of	epilepsy	syndromes	(Table	1).	On	average,	88%	of	the	target	(27	genes)	was	covered	at	50X	or	higher	with	a	per-gene	range	of	69.65%	(GRIN1)	to	99.04%	(GABRB1)	(Fig.	S1).			Pathogenic	or	likely	pathogenic	variants	were	discovered	in	7	of	the	27	genes	(ALG13,	CACNA1A,	DNM1,	GABRB3,	GNAO1,	IQSEC2,	SLC1A2),	accounting	for	17/531	cases	or	3.2%	of	the	entire	cohort	(Table	2).	Mutations	in	GABRB3	(n=7)	and	
CACNA1A	(n=4)	accounted	for	the	largest	proportion	of	individuals.	Recurrent	mutations	were	identified	in	six	genes	(ALG13,	CACNA1A,	DNM1,	GABRB3,	GNAO1,	
SLC1A2).	An	additional	six	variants	of	uncertain	significance	(VOUS)	were	detected	(Table	S1).			We	identified	two	individuals	with	de	novo	mutations	in	SLC1A2	(MIM:	600300),	establishing	this	as	an	EE	gene	(p=0.0052).	Previously	only	a	single	individual	with	IS	and	a	de	novo	missense	mutation	was	reported	1.	SLC1A2	encodes	Excitatory	Amino	Acid	Transporter	2	(EAAT2),	one	of	the	major	glutamate	transporters	expressed	in	astroglia	that	is	responsible	for	clearing	glutamate	from	the	extracellular	space	at	the	synapse	12.	One	individual	from	our	study	shares	the	same	missense	mutation	(NM_004171.3:c.244G>C[p.Gly82Arg])	as	the	original	IS	individual	while	the	other	person	has	a	novel	mutation	(NM_004171.3:c.254T>C[p.Leu85Pro])	(Figure	S2).	Microsatellite	testing	confirmed	that	the	two	cases	with	the	p.Gly82Arg	were	different	individuals.	These	mutations	cluster	in	the	first	extracellular	domain	of	this	transmembrane	protein.			Our	individuals	with	SLC1A2	mutations	presented	with	an	extremely	severe	phenotype	with	profound	impairment	from	birth	without	detectable	regression	and	seizure	onset	in	the	first	week	of	life.	The	original	IS	individual	had	seizure	onset	in	the	neonatal	period	(Table	3).	All	3	individuals	had	multiple	seizure	types	with	prominent	myoclonic	and	tonic	seizures	as	well	as	spasms.	One	(T23159)	had	profound	growth	failure	with	microcephaly	(at	age	17	years:	weight	15	kg,	height	
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and	head	circumference	49	cm),	which	was	not	observed	in	the	remaining	two	cases.			We	identified	seven	individuals	with	GABRB3	mutations,	a	gene	previously	reported	with	de	novo	mutations	in	four	individuals	with	LGS	or	IS	1.	The	seven	new	individuals	presented	with	somewhat	heterogeneous	phenotypes	of	LGS	(1),	epilepsy	with	myoclonic-atonic	seizures	(1),	and	unclassified	epileptic	encephalopathy	(4).	The	seventh	case	had	features	reminiscent	of	Dravet	syndrome	but	could	be	distinguished	by	the	absence	of	typical	Dravet	features	including	generalized	spike	wave	activity,	hemiclonic	and	focal	seizures,	although	it	is	recognized	that	these	features	are	not	universal	in	Dravet	syndrome	(Table	4).	For	this	case,	the	variant	segregated	in	a	family	with	genetic	epilepsy	and	febrile	seizures	plus	(GEFS+).		Collectively,	ten	of	the	eleven	individuals	we	found	to	carry	a	GABRB3	de	novo	missense	mutation	had	seizure	onset	by	1	year	of	age,	occurring	in	the	context	of	either	preceding	normal	(3)	or	slow	(6)	development	(details	unknown	for	1),	whereas,	one	child	with	developmental	delay	had	seizure	onset	at	12	years	(Table	4).	Five	had	severe	to	profound	intellectual	disability,	three	mild	to	moderate	disability	and	the	degree	of	cognitive	impairment	was	unclear	in	the	remaining	three.	Predominant	seizure	types	were	myoclonic,	tonic,	absence	and	generalized	tonic-clonic	seizures.	One	individual	had	epileptic	spasms.			Five	of	the	eleven	pathogenic	GABRB3	variants	clustered	in	the	transmembrane	domains	at	evolutionarily	conserved	sites	(average	GERP	5.54±0.4,	nucleotide	resolution).	Six	pathogenic	variants,	including	the	recurrent	mutation,	are	dispersed	throughout	the	N-terminal	extracellular	domain	at	well-conserved	residues	(average	GERP	5.38±0.4,	nucleotide	resolution).	One	novel	variant	in	GABRB3	was	classified	as	‘likely	pathogenic’	because	inheritance	information	was	limited	but	the	amino	acid	change	from	a	polar	to	a	basic	residue	in	the	transmembrane	domain	(Figure	S3),	and	a	CADD	score	>25	and	PolyPhen-2	of	0.992	(probably	damaging)	predicted	a	likely	damaging	effect	on	protein	function.		
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	Pathogenic	mutations	in	CACNA1A	were	identified	in	four	probands	and	one	affected	sibling.	Deep	sequencing	of	the	parents	with	two	affected	children	revealed	that	the	unaffected	mother	was	a	mosaic	carrier	with	a	6.3%	mutant	allelic	fraction	in	lymphocyte-derived	DNA.	Two	probands	and	the	affected	sibling	have	a	recurrent	mutation	(NM_023035.2:c.2137G>A[p.Ala713Thr])	first	identified	in	our	original	study	1.	This	number	of	de	novo	missense	mutations	in	our	cohort	represents	a	significant	enrichment	(p=	8.0	x	10-5),	providing	clear	evidence	that	de	novo	mutations	in	CACNA1A	cause	epileptic	encephalopathy.			For	the	six	CACNA1A	cases,	seizures	began	on	the	first	day	of	life	in	five	with	the	siblings	having	in	utero	movements	suggestive	of	seizures	described	as	“butterfly	wings	rapidly	flapping”.	Seizures	were	recognized	by	2	hours	of	age	in	three	infants	(Table	5).		For	the	remaining	case,	onset	was	at	4	weeks.	Three	individuals,	including	the	sibling	pair,	initially	had	myoclonic	seizures,	while	three	presented	with	convulsive	seizures	with	tonic	or	tonic	clonic	features.	Multiple	seizure	types	developed	in	each	case	and	included	focal,	tonic	and	tonic-clonic	seizures.	Status	epilepticus	occurred	in	all,	including	at	seizure	onset	in	one	case.	A	reflex	component	was	observed	in	the	siblings	with	their	myoclonic	seizures	triggered	by	touch	and	noise	and	in	the	original	case	with	LGS.		EEG	studies	showed	multifocal	epileptiform	activity	in	three	individuals,	generalized	spike	wave	and	polyspike	wave	in	two	individuals	and	multifocal	slowing	in	one.	Development	was	delayed	in	all	with	five	individuals	having	severe	ID	and	one	moderate	ID.	Cerebral	palsy	was	observed	in	all	with	variable	features	(Table	5).	Ophthalmic	findings	included	strabismus	(1)	and	nystagmus	(2).	Motor	features	included	ataxia	(3),	tremor	(2)	and	athetosis	(1).			We	also	identified	one	individual	each	with	a	recurrent	mutation	in	DNM1,	GNAO1	and	ALG13	(Table	S2).	In	the	case	with	a	DNM1	mutation	(NM_004408.2:c.709C>T[p.Arg237Trp]),	one	proband	with	an	apparent	de	novo	p.Arg237Trp	mutation	had	a	similarly	affected	sibling	who	carried	the	same	
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mutation.	Deep	sequencing	of	the	unaffected	parents	confirmed	somatic	mosaicism	in	the	father	with	a	5.5%	mutant	allelic	fraction	in	blood-derived	DNA.	The	siblings	had	onset	of	seizures	at	1	month	and	4	months	of	age	with	multiple	seizure	types,	severe	to	profound	delay	and	prominent	movement	disorder	features.		A	recurrent	mutation	in	GNAO1	(NM_020988.2:c.836T>A[p.Ile279Asn])	was	identified	in	a	2	year	old	boy	with	EOEE.	All	11	reported	individuals	with	mutations	in	GNAO1	are	female	despite	GNAO1	being	located	on	chromosome	16.	Seizures	may	have	begun	in	utero	with	unusual	movements	from	32	weeks	gestation.	Apnoeic	episodes	began	at	26	minutes	of	age	with	20	episodes	per	day.	At	9	days,	focal	clonic	seizures	of	the	face	were	noted.	Unusual	jerky	movements,	involving	the	eyes	as	well,	began	at	4	months	followed	by	extensor	spasms.	Tonic	seizures	developed	at	16	months.	Development	was	never	normal	with	regression	with	the	onset	of	spasms	and	hypsarrhythmia	on	EEG,	and	subsequent	profound	impairment.				We	also	report	the	eighth	female	with	a	recurrent	mutation	(NM_001099922.2:c.320A>G[p.Asn107Ser])	in	ALG13,	which	is	located	on	the	X	chromosome.	The	ALG13	p.107Ser	had	previously	arisen	de	novo	in	seven	other	reported	females;	the	father	of	our	case	was	not	available	1;	13-15.	Microsatellite	testing	confirmed	our	case	was	not	related	to	the	two	individuals	we	reported	previously	1.	Our	case	showed	minimal	responsiveness	prior	to	onset	of	tonic	seizures	at	1-2	months	with	spasms	developing	at	4	months.	She	had	profound	impairment	with	hypotonia	and	choreoathetoid	movements.	Seizures	were	refractory;	vigabatrin	increased	spasms	and	her	movement	disorder.		There	is	limited	data	on	previous	cases	but	common	features	include	infantile	spasms	(7/7),	severe	to	profound	intellectual	disability	(6/7),	visual	impairment	(2/7)	and	hypotonia	(2/7).			Finally,	we	identified	a	42	year	old	woman	with	a	de	novo	nonsense	mutation	in	
IQSEC2	(NM_001111125.1:c.2203C>T[p.Gln735*]),	a	known	cause	of	X-linked	intellectual	disability	16.	She	had	preceding	mild	developmental	delay	when	she	
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presented	at	5	years	with	nonconvulsive	status	epilepticus	with	absence	seizures,	tonic-clonic	seizures	and	drop	attacks,	associated	with	regression.	She	later	developed	myoclonic	seizures.			
	
DISCUSSION	Our	study	of	531	individuals	with	unsolved	EEs	highlights	the	value	of	large-scale	studies	to	secure	the	role	of	novel	disease-associated	genes,	given	the	marked	genetic	heterogeneity	underlying	the	EEs	17.		We	performed	targeted	sequencing	of	27	genes	drawn	from	more	than	290	genes	identified	with	a	de	novo	variant	in	a	cohort	of	264	individuals	with	two	specific	EEs:	infantile	spasms	and	Lennox-Gastaut	syndrome.	We	identified	17	(3.2%)	cases	with	a	causative	mutation.		By	finding	additional	cases	with	de	novo,	and	sometimes	recurrent,	mutations	in	a	novel	gene,	we	strengthen	the	case	for	pathogenicity	of	that	gene.	Our	results	provide	evidence	for	SLC1A2	as	a	novel	cause	of	EE,	and	we	refine	the	phenotypes	of	EEs	associated	with	mutations	in	GABRB3	(7/531,	1.3%)	and	CACNA1A	(4/531,	0.8%),	which	accounted	for	the	largest	proportion	of	cases	with	mutations	identified	in	our	cohort.	As	larger	cohorts	of	a	new	genetic	EE	are	assembled,	the	efficacy	(or	exacerbation)	of	specific	anti-epileptic	therapies	can	be	established.	Moreover,	understanding	the	functional	consequences	of	specific	mutations	will	pave	the	way	to	precision	medicine.		We	report	conclusive	evidence	that	mutations	in	SLC1A2	cause	an	EE;	the	phenotype	is	extremely	severe	with	seizure	onset	in	the	first	week	of	life,	multiple	seizure	types	including	tonic	and	myoclonic	seizures,	and	profound	impairment.	SLC1A2	encodes	one	of	the	major	glutamate	transporters,	EAAT2.	Mutations	in	Slc1a2	in	mice	lead	to	impaired	glutamate	uptake	causing	excess	glutamate	and	subsequent	excitotoxicity	18.	Null	mice	exhibit	lethal	spontaneous	epileptic	seizures	with	very	few	animals	surviving	beyond	13	weeks	18.	Functional	studies	are	required	to	determine	if	our	mutations	cause	haploinsufficiency;	if	so,	recently	identified	translational	enhancers	of	EAAT2	may	offer	a	novel	therapeutic	approach	19;	20.		
Epi4K	Consortium	
	
11	
11	
	For	GABRB3,	our	studies	have	now	identified	a	total	of	11	cases	with	a	wide	phenotypic	spectrum,	accounting	for	more	than	1%	of	unsolved	EEs.	Seizure	onset	in	10/11	cases	occurred	in	the	first	year	of	life	with	myoclonic,	tonic,	absence	and	generalized	tonic-clonic	seizures;	spasms	were	rare.	Early	development	could	be	normal	or	delayed;	intellectual	outcome	varied	from	severe	to	mild.	Recent	case	reports	include	two	boys	with	an	EOEE	attributed	to	an	in-frame	insertion	in	
GABRB3	in	one	case	and	a	de	novo	p.Thr287Ile	substitution	in	the	second	case21;	22.		
CACNA1A	encodes	the	alpha1	subunit	of	the	Cav2.1	P/Q-type	calcium	channel	and	was	first	reported	as	a	gene	for	episodic	ataxia	type	2	(OMIM:	18500),	spinocerebellar	ataxia	6	(OMIM:	18036)	and	familial	hemiplegic	migraine	type	1	(OMIM:	145100).	CACNA1A	is	amongst	the	2%	most	intolerant	genes	in	the	human	genome	3.	Although	deletions	that	include	CACNA1A	and	a	single	truncating	mutation	have	been	associated	with	EE	23-25,	we	show	that	de	novo	missense	mutations	can	also	cause	a	severe	EE	in	six	individuals.	Seizures	began	on	the	first	day	of	life	in	5/6	cases	typically	including	focal,	tonic	and	tonic-clonic	seizures.	Myoclonic	seizures	were	observed	sometimes	with	a	prominent	reflex	component.	Severe	ID	was	usual	and	a	range	of	motor	features	were	observed.	All	individuals	had	missense	mutations	that	clustered	in	the	transmembrane	domains	of	this	multi-pass	transmembrane	protein	(Figure	S4).			Seven	of	our	17	(41%)	mutations	were	recurrent,	having	been	reported	in	at	least	one	affected	individual.	The	DNM1	p.Arg237Trp	mutation	is	located	in	a	CpG	dinucleotide,	a	known	mutation	hotspot	26.	The	recurrence	of	the	SLC1A2	p.Gly82Arg	mutation	may	be	accounted	for	by	a	homopolymer	stretch	of	guanines.	Sequence	context	does	not	appear	to	explain	the	recurrence	of	the	other	mutations.		The	most	notable	example	of	recurrence	is	the	p.Asn107Ser	mutation	in	ALG13,	which	has	now	been	reported	in	seven	affected	females.	Although	loss	of	ALG13	function	causes	glycosylation	defects	in	boys,	two	female	individuals	had	normal	glycosylation	levels	on	biochemical	testing	13;	14,	invoking	an	alternative	mechanism.		
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	In	2/14	families	in	which	we	identified	a	mutation	and	were	able	to	test	both	parents,	we	found	the	apparently	‘de	novo’	mutation	in	a	similarly	affected	sibling.	Deep	sequencing	in	both	sets	of	parents	confirmed	low-level	somatic	mosaicism	of	around	6%	in	one	parent.	This	finding	mirrors	a	recent	Dravet	syndrome	study	in	which	one	parent	of	a	child	with	an	apparently	de	novo	SCN1A	mutation	had	low,	but	detectable,	levels	of	mosaicism	in	~10%	of	cases	27.	This	has	critical	implications	for	recurrence	risk	calculations,	reproductive	choices	and	prenatal	counseling.			There	are	several	possible	limitations	to	our	study.	First,	from	the	phenotypic	viewpoint,	the	discovery	cohort	included	individuals	with	IS	or	LGS,	while	this	cohort	included	much	more	diverse	EEs	(Table	1).	Of	the	531	individuals	screened,	90	had	IS	and	41	LGS,	meaning	>75%	of	the	cohort	had	other	EEs.	If	mutations	in	some	of	these	genes	specifically	cause	IS	or	LGS,	our	cohort	may	be	too	small	to	detect	additional	mutations.	However,	as	the	majority	of	individuals	in	our	cohort	with	a	mutation	did	not	have	IS	or	LGS,	our	findings	highlight	the	importance	of	screening	broader	populations	of	EEs	to	define	the	phenotypic	spectrum	of	new	genetic	diseases.			From	the	molecular	standpoint,	we	acknowledge	that	mutations	may	remain	undetected	due	to	suboptimal	coverage	of	a	given	gene	or	in	a	given	individual.	Some	genomic	regions	are	less	amenable	to	sequencing	with	the	molecular	inversion	probe	technology	28.	Moreover,	our	conservative	requirement	of	50X	coverage	for	variant	calling	could	result	in	reduced	sensitivity.	Finally,	it	is	important	to	note	that	not	all	329	de	novo	variants	identified	in	our	original	WES	study	are	pathogenic.	The	lack	of	mutations	in	some	candidate	genes	in	our	panel	may	be	because	these	genes	are	not	relevant	to	EE	pathogenesis,	or	perhaps	they	explain	a	far	smaller	fraction	of	the	EE	population.	Sequencing	additional	individuals	and	combining	large	datasets	will	facilitate	identifying	additional	EE	genes	among	the	candidate	genes	from	the	original	study.		
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In	summary,	we	identified	mutations	in	17/531	probands,	with	pathogenic	variants	in	7/27	genes	selected	for	targeted	sequencing.	There	are	6	additional	variants	of	unknown	significance	(Table	S1)	but	further	genetic	and	functional	studies	are	required	to	determine	if	they	are	pathogenic.	GABRB3	and	CACNA1A	explained	the	largest	proportion	of	cases	in	this	study	providing	a	molecular	cause	for	1.3%	(7/531)	and	0.8%	(4/531)	individuals	respectively;	we	also	confirm	SLC1A2	as	an	EE	gene.	Importantly,	our	study	highlights	the	role	of	recurrent	mutations,	the	relevance	of	parental	mosaic	transmission,	and	the	genetic	and	phenotypic	heterogeneity	of	the	EEs.	
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Table	1.	Epilepsy	syndromes	in	unsolved	cohort	of	individuals	with	EEs	
	
Diagnosis	 No.	Epileptic	encephalopathy	unclassified	 205	Infantile	spasms	 90	Epilepsy	with	myoclonic-atonic	seizures	 80	Lennox-Gastaut	syndrome	 41	Early	onset	epileptic	encephalopathy	(seizure	onset	≤3	months)	 33	Epilepsy	aphasia	syndrome	 20	Dravet	syndrome	(SCN1A	negative)	 15	Febrile	infection-related	epilepsy	syndrome		 14	Epileptic	encephalopathy	with	continuous	diffuse	spike-waves	during	slow-wave	sleep	 13	Epilepsy	of	infancy	with	migrating	focal	seizures	 8	Atypical	benign	partial	epilepsy	of	childhood	 7	Early	myoclonic	encephalopathy	 4	Early	infantile	epileptic	encephalopathy	(Ohtahara	syndrome)		 1		 	
Total	individuals		 531	
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Table	2.	Pathogenic	and	likely	pathogenic	variants	in	EE	genes	identified	in	this	study	
	DS,	Dravet	syndrome;	EE,	epileptic	encephalopathy;	EIEE,	early	infantile	epileptic	encephalopathy;	EIMFS,	epilepsy	of	infancy	with	migrating	focal	seizures;	EME,	early	myoclonic	encephalopathy;	EOEE,	early	onset	epileptic	encephalopathy;	GEFS+,	Generalized	epilepsy	with	febrile	seizures	plus;	ID,	intellectual	disability;	IS,	infantile	spasms;	LGS,	Lennox-Gastaut	syndrome;	MAE,	epilepsy	with	myoclonic-atonic	seizures;	SGE,	symptomatic	generalised	epilepsy;	VOUS,	variant	of	unknown	significance	a	Recurrent	mutation	that	has	previously	been	reported	as	causing	EE.	b	Previously	reported	29.	c	Clinical	Variant	(rs121908225)	associated	with	Familial	hemiplegic	migraine	type	1	with	progressive	cerebellar	ataxia.		
Gene	 Proband	
(Sex)	
Inheritance	 Inferred	
Effect	
GRCh37/hg19	
Genomic	Coordinate	
cDNA	Change	 Protein	Change	 CADD	 Diagnosis	
SLC1A2	 EG1291	(F)	 De	novo	 Pathogenic	a	 chr11:g.35336636	 NM_004171.3:c.244G>C	 p.Gly82Arg	 26.0	 EOEE	
	 T23159	(F)	 De	novo	 Pathogenic	 chr11:g.35336626	 NM_004171.3:c.254T>C	 p.Leu85Pro	 22.3	 EME	
GABRB3	 EG0254	(M)	 De	novo	 Pathogenic	a	 chr15:g.26866564	 NM_000814.4:c.358G>A	 p.Asp120Asn	 36.0	 MAE		 EG0258	(M)	 Segregates	with	GEFS+	family	 Pathogenic	 chr15:g.26828553	 NM_000814.4:c.470C>T	 p.Thr157Met	 24.4	 DS-like		 T22598	(F)	 De	novo	 Pathogenic	b	 chr15:g.	26825603	 NM_000814.4:c.545A>T	 p.Tyr182Phe	 32.0	 EE		 T25111	(F)	 De	novo	 Pathogenic	 chr15:g.26812818	 NM_000814.4:c.745C>A	 p.Gln249Lys	 29.7	 EE		 EG1542	(M)	 De	novo	 Pathogenic	 chr15:g.26812796	 NM_000814.4:c.767T>A	 p.Leu256Gln	 17.6	 EOEE		 T23950	(F)	 Unknown	 Likely	pathogenic	 chr15:g.26806281	 NM_000814.4:c.878T>A	 p.Leu293His	 25.1	 EOEE		 T25708	(M)	 De	novo	 Pathogenic	 chr15:g.26806246	 NM_000814.4:c.913G>A	 p.Ala305Thr	 35.0	 LGS	
CACNA1A	 EG1371	(M)	 De	novo	 Pathogenic	 chr19:g.13566019	 NM_023035.2:c.301G>C	 p.Glu101Gln	 19.1	 EIMFS		 T21924	(F)	 Unknown,	father	unavailable	 VOUS	c	 chr19:g.13476262	 NM_023035.2:c.653C>T	 p.Ser218Leu	 16.6	 EOEE		 T23039	(F)	 De	novo	 Pathogenic	a	 chr19:g.13414398	 NM_023035.2:c.2137G>A	 p.Ala713Thr	 22.1	 EOEE		 T24139	(M)	 Mosaic	mother	 Pathogenic	a	 chr19:g.13414398	 NM_023035.2:c.2137G>A	 p.Ala713Thr	 22.1	 EOEE		 EG1519	(F)	 De	novo	 Pathogenic	 chr19:g.13368235	 NM_023035.2:c.4531G>T	 p.	Ala1511Ser	 20.2	 EOEE	
DNM1	 T24107	(F)	 Mosaic	parent	 Pathogenic	a	 chr9:g.130982480	 NM_004408.2:c.709C>T	 p.Arg237Trp	 19.9	 EE	
GNAO1	 T25023	(M)	 De	novo	 Pathogenic	a	 chr16:g.56385408	 NM_020988.2:c.836T>A	 p.Ile279Asn	 28.6	 EOEE	
IQSEC2	 T17563	(F)	 De	novo	 Pathogenic	 chrX:g.53279555	 NM_001111125.1:c.2203C>T	 p.Gln735*	 39.0	 SGE	
ALG13	 T22647	(F)	 Unknown,	father	unavailable	 Pathogenic	a	 chrX:g.110928268	 NM_001099922.2:c.320A>G	 p.Asn107Ser	 21.0	 EOEE	
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Table	3.	Clinical	features	of	individuals	with	SLC1A2	mutations		
Identifier	 Age	
Gender	
Epilepsy	
syndrome	
Development	
prior	to	
seizure	onset	
Age	of	
seizure	
onset	
Seizure	
type	at	
onset	
Development	
after	seizure	
onset	
Other	seizure	
types	
Age	of	
seizure	
offset	
EEG	 Neuroimaging	 Other	features	 Medicationsa	
Individuals	identified	in	this	cohort	T23159	 17y	F	 EME	 Never	normal	 2d	 Myoclonic	(virtually	continuous	multifocal	twitching,	particularly	in	sleep)		
Profound	ID	 Tonic	(generalised	and	focal)	Myoclonic	SE	Possible	NCSE		
Ongoing	 Multifocal	Slow	background		 3m:	normal		1y:	almost	complete	absence	of	myelination	of	cerebrum	with	normal	myelination	of	cerebellum	and	brain	stem,	thin	CC,	T2	hyperintensity	in	lentiform	nuclei		3y:	cerebral	atrophy,	complete	absence	of	myelination	of	subcortical	and	periventricular	white	matter,	normal	myelination	of	cerebellum,	brain	stem,	thalami	and	basal	ganglia,	thin	CC,	thinning	of	cortical	grey	matter,	no	cerebellar	atrophy		13y:	extreme	supratentorial	atrophy	involving	cortex,	deep	grey	matter	and	white	matter.	Sparing	of	posterior	fossa	with	brainstem	and	cerebellum	are	of	normal	size	and	signal	intensity	
Severe	asymmetric	quadriparesis	Gastrostomy	Bilateral	nephrocalcinosis,	Amenorrhoea	Delayed	dentition	Frequent	bradycardia	and	hypothermia	exacerbated	by	sleep	and	anaesthesia	Progressive	microcephaly	with	bitemporal	narrowing	Severe	growth	failure	(15kg	at	16y)	Hirsuitism	Severe	kyphoscoliosis	Joint	contractures	with	tapering	fingers	
CBZ,	LTG,	LCM,	pyridoxine,	CZP,	AZD,	VPA,	PB,	PHT,	prednisolone,	VGB,	KD,	TPM	
EG1291	 6y	F	 EOEE	 Never	normal	 5d	 Epileptic	spasms	 Profound	ID	 Myoclonic	Myoclonic	SE	Tonic	Tonic-clonic	Focal	
Ongoing	 Multifocal	(no	hypsarrhythmia)	 6m:	Delayed	myelination	3y:	Progress	in	myelination,	frontal	atrophy,	thin	CC	 Mild-moderate	generalized	hypotonia	Father:	2	seizures	as	an	adult,	no	further	seizures	on	LTG	 LEV,	VPA,	pyridoxine,	VGB,	prednisolone,	ZNS,	KD	
Individuals	identified	in	Epi,	Epilepsy	Phenome/Genome	et	al.	2013	n	 8y	F	 IS	 Unknown	 1mth	 Focal	tonic	Myoclonic	 Some	regression	Severe	ID	 	 Unknown	 Hypsarrhythmia	Disorganised	background	Bifrontal	central	frequent	discharges	
Normal	 Blindness	Bilateral	hamstring	contractures	Torticollis	Extensor	plantar	response	on	L	and	flexor	on	R	Head	lag	Axial	hypotonia	Mild	appendicular	hypertonia		
VGB,	OCBZ,	TPM,	PB,	LEV	
	ACTH,	adrenocorticotropic	hormone;	ADHD,	attention	deficit	hyperactivity	disorder;	AZD,	acetazolamide;	CBZ,	carbamazepine;	CC,	corpus	callosum;	CLB,	clobazam;	CLZ,	clorazepate;	C-PAP,	continuous	positive	airway	pressure;	CSF,	cerebral	spinal	fluid;	CT,	computed	tomography;	CSE,	convulsive	status	epilepticus;	CZP,	clonazepam;	d,	days;	DZP,	diazepam;	EE,	epileptic	encephalopathy;	EIEE,	early	infantile	epileptic	encephalopathy;	EIMFS,	epilepsy	of	infancy	with	migrating	focal	seizures;	EME,	early	myoclonic	encephalopathy;	EOEE,	early	onset	epileptic	encephalopathy;	ETX,	ethosuxamide;	F,	female;	FBM,	felbamate;	FIAS,	focal	impaired	awareness	seizure;	FS,	febrile	seizures;	GBP,	gabapentin;	GORD,	gastro-oesophageal	reflux	disease;	GPFA,	generalised	paroxysmal	fast	activity;	GSW,	generalised	spike	wave;	h,	hours;	ID,	intellectual	disability;	IS,	infantile	spasms;	KD,	ketogenic	diet;	kg,	kilograms;	L,	left;	LCM,	lacosamide;	LEV,	levetiracetam;	LTG,	lamotrigine;	LGS,	Lennox-Gastaut	Syndrome;	M,	male;	MAD,	modified	Atkins	diet;	MDZ,	midazolam;	mth,	months;	NCSE,	non-convulsive	status	epilepticus;	NG,	nasogastric;	NICU,	neonatal	intensive	care	unit;	NZP,	nitrazepam;	OCBZ,	oxcarbazepine;	PB,	phenobarbitone;	PFA,	paroxysmal	fast	activity;	PHT,	phenytoin;	PRM,	primidone;	PSW,	polyspike	wave;	PEG,	percutaneous	endoscopic	gastrostomy;	R,	right;	RFM,	rufinamide;	sec,	seconds;	SE,	status	epilepticus;	SGE,	symptomatic	generalised	epilepsy;	SPECT,	single-photon	emission	computed	tomography;	STP,	stiripentol;	SSW,	slow	spike	wave;	TPM,	topiramate;	VGB,	vigabatrin;	VNS,	vagus	nerve	stimulation;	VPA,	valproate;	w,	weeks;	y,	years;	ZNS,	zonisamide	a	medications	current	at	last	follow-up	underlined	 	
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Table	4.	Clinical	features	of	individuals	with	GABRB3	mutations		
Identifier	 Age	
Gender	
Epilepsy	
syndrome	
Development	
prior	to	seizure	
onset	
Age	of	
seizure	
onset	
Seizure	type	
at	onset	
Development	
after	seizure	
onset	
Other	seizure	types	 Age	of	
seizure	
offset	
EEG	 Neuroimaging	 Other	features	 Medications	a	
Individuals	identified	in	this	cohort	T25111	 19y	F	 EE	 Delayed	at	6m	 12y	 Tonic-clonic	 Severe	ID	 Absence	Atonic	Tonic-clonic	CSE	Focal	impaired	awareness	evolving	to	bilateral	convulsion	Tonic	
Ongoing	 Generalised	Atypical	fast	background	Right	and	bisynchronous	epileptiform	activity	PFA	Multifocal		
Normal	 Pain	insensitivity	Transient	balance	issues	Ataxia	Dyspraxia	Behavioural	issues	Aggression	Autism	Gum	hypertrophy	(PHT	use)	
LTG,	VPA,	ZNS,	PHT,	CLB,	CZP,	CBZ,	LCM,	LEV,	TPM	
T22598	 SUDEP	2y	11mth	F	 EE	 Delayed	 6mth	 Facial	grimace	and	horizontal	head	shaking	with	retained	awareness	
Delayed	 Tonic-clonic	Focal	with	retained	awareness	Focal	SE	Atonic	Atypical	absence	Tonic	
Ongoing	at	death	 Multifocal	Slow	background	 Incomplete	myelination	Plagiocephaly	 Autistic	features	 PB,	CBZ,	MAD	
T25708	 14y	M	 LGS	 Never	normal	Feeding	via	NG	tube	from	5m	 5mth	 Altered	facial	expression,	choking,	stiffening	of	arms,	eye	rolling		
Severe	ID	 Tonic-clonic	Atypical	absence	Tonic	Myoclonic		Episodes	of	kicking	or	thrashing	of	limbs	and	body		Bouts	of	laughter	lasting	<3	minutes	
Ongoing	 Almost	continuous	GSW	Slow	background	Multifocal	SSW	GPFA	
8m:	mild	prominence	of	ventricles	and	subarachnoid	spaces	2y:	atrophy	and	hypomyelination	of	central	white	matter	and	ventricles	6y:	delayed	but	progressing	myelination,	empty	sella	with	flattened	pituitary	gland	11y:	normal		
PEG	feeding	Microcephaly	Scoliosis	Cerebral	palsy	Visual	and	hearing	impairment	Sleep	disturbance	
LTG,	LEV,	VPA,	PB	
T23950	 7y	M	 EOEE	 Never	normal	 1mth	 Myoclonic			 Profound	ID	 Tonic	Focal	motor	Clonic	 Unknown	(lost	to	follow	up)	 Multifocal	sharp	waves	 Cortical	atrophy	Thin	CC	Increased	T2	in	globus	pallidus	
Congenital	unilateral	ptosis	Constipation	Hypotonia	Drooling	Dysmorphic	features	
VGB,	PB,	TPM	
EG0258	 9y	M	 Dravet	syndrome-like	 Normal	 8mth	 Febrile		Tonic-clonic	 Mild	ID	Delayed	by	2.5y	 Tonic-clonic	Absence	Myoclonic	Atonic	
Ongoing	 Frontal,	temporal	and	central	sharp	waves	Frontal	and	temporal	R		sharp	waves	
Normal	 Severe	ADHD	Fever	sensitive	seizures	 LTG,	LEV,	STP	
EG1542	 3y	M	 EOEE	 Unknown	 1d	 Tonic-clonic	 Delayed	by	3mth	Severe	ID	 Spasms	Focal	motor	Tonic	 Ongoing	 Hypsarrhythmia	Polymorphous	delta	intermixed	with	polyspikes	Diffuse	background	slowing	
Hypomyelination	 Diffuse	hypotonia	Dyskinesia	 PB,	VGB,	hydrocortisone,	VPA,	LEV,	CLB,	KD	EG0254	 12y	M	 MAE	 Normal	 1y	 Febrile		Tonic-clonic	 Mild	ID	Delayed	by	2.5y	 Myoclonic-atonic	Atonic	Myoclonic	Absence	
1.5y	 2.5-3Hz	GSW	Diffuse	slowing	 Normal	 Stereotyped	behaviour	Learning	disability	 VPA,	LTG,	CLB,	ETX,	TPM	(seizure	free	on	LEV	+	VPA	+	TPM)	
Individuals	identified	in	Epi,	Epilepsy	Phenome/Genome	et	al.	2013	dr	 13y	F	 IS	 Normal	 5mth	 Infantile	Spasms	 Mild	delay	 Myoclonic	Focal	impaired	awareness	 Unknown	 Hypsarrhythmia	evolved	from	multifocal	discharges	Background	slowing	 Normal	 Recurrent	infections	Epiphora	 TPM,	ACTH	gs	 18y	F	 LGS	 Delayed	 10mth	 Focal	impaired	awareness	 Severe	ID	 Tonic-clonic	CSE	 Unknown	 Generalised	slowing	GSW	Bilateral	synchronous	L>R	sharp	waves	or	spikes	L	temporal	or	generalised	onset	to	seizures	L	temporal	paroxysmal	features	Bilateral	independent	
Normal	 Hypertonia	in	legs,	especially	ankles	 PB,	CBZ,	VPA,	PHT,	CZP,	TPM,	FBM	
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hemispheric	seizures	Bilateral	independent	sharp	waves	or	spike	in	temporal	and	occipital	regions	jw	 20y	M	 LGS	 Mild	delay	 10mth	 IS	 Mild	ID	 Tonic-clonic	Atypical	absence	Myoclonic	Atonic	
Unknown	 2Hz	sharp-spike	wave	Bilateral	occipital	slow	wave	Asymmetric	photic	driving	Poorly	organised	background	Multifocal	
Normal	 ADHD	Mood	lability	Impulsive	behaviour	Distractible	Hyperactive	Acts	out	Aggression	Psychosis	Drooling	Clumsy	Mild	dysmorphism	
VPA,	TPM,	LTG,	CBZ,	LEV,	FBM,	VNS	
jr	 11y	M	 LGS	 Delayed	 10mth	 IS	(some	letters	say	FS,	shortly	after	birth	Mum	noticed	jerking	movements)	
Moderate	ID	 FS	Tonic-clonic	Tonic	Atypical	absence	Myoclonic	Atonic	
Unknown	 Generalised	2Hz	discharges	Irregular	spikes	with	myoclonic	jerks	and	accounting	for	40-50%	of	sleep	recording	Slow	background	
Small	acute	infarct	in	splenium	of	CC	 Sleeping	difficulties	ADHD	Impulsive	behaviour	Echopraxia	Distractible	Hypotonia	but	normal	strength	Dyspraxia	Dysarthria	Dyspraxic	fine	and	gross	motor	skills	
Prednisolone,	ZNS,	LTG,	AZD,	CZP,	LEV,	VPA	
		ACTH,	adrenocorticotropic	hormone;	ADHD,	attention	deficit	hyperactivity	disorder;	AZD,	acetazolamide;	CBZ,	carbamazepine;	CC,	corpus	callosum;	CLB,	clobazam;	CLZ,	clorazepate;	C-PAP,	continuous	positive	airway	pressure;	CSF,	cerebral	spinal	fluid;	CT,	computed	tomography;	CSE,	convulsive	status	epilepticus;	CZP,	clonazepam;	d,	days;	DZP,	diazepam;	EE,	epileptic	encephalopathy;	EIEE,	early	infantile	epileptic	encephalopathy;	EIMFS,	epilepsy	of	infancy	with	migrating	focal	seizures;	EME,	early	myoclonic	encephalopathy;	EOEE,	early	onset	epileptic	encephalopathy;	ETX,	ethosuxamide;	F,	female;	FBM,	felbamate;	FIAS,	focal	impaired	awareness	seizure;	FS,	febrile	seizures;	GBP,	gabapentin;	GORD,	gastro-oesophageal	reflux	disease;	GPFA,	generalised	paroxysmal	fast	activity;	GSW,	generalised	spike	wave;	h,	hours;	ID,	intellectual	disability;	IS,	infantile	spasms;	KD,	ketogenic	diet;	kg,	kilograms;	L,	left;	LCM,	lacosamide;	LEV,	levetiracetam;	LTG,	lamotrigine;	LGS,	Lennox-Gastaut	Syndrome;	M,	male;	MAD,	modified	Atkins	diet;	MDZ,	midazolam;	mth,	months;	NCSE,	non-convulsive	status	epilepticus;	NG,	nasogastric;	NICU,	neonatal	intensive	care	unit;	NZP,	nitrazepam;	OCBZ,	oxcarbazepine;	PB,	phenobarbitone;	PFA,	paroxysmal	fast	activity;	PHT,	phenytoin;	PRM,	primidone;	PSW,	polyspike	wave;	PEG,	percutaneous	endoscopic	gastrostomy;	R,	right;	RFM,	rufinamide;	sec,	seconds;	SE,	status	epilepticus;	SGE,	symptomatic	generalised	epilepsy;	SPECT,	single-photon	emission	computed	tomography;	STP,	stiripentol;	SSW,	slow	spike	wave;	TPM,	topiramate;	VGB,	vigabatrin;	VNS,	vagus	nerve	stimulation;	VPA,	valproate;	w,	weeks;	y,	years;	ZNS,	zonisamide	a	medications	current	at	last	follow-up	underlined	 	
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Table	5.	Clinical	features	of	individuals	with	CACNA1A	mutations		
Case	 Age	
Gender	
Epilepsy	
syndrome	
Development	
prior	to	
seizure	onset	
Age	of	
seizure	
onset	
Seizure	type	at	
onset	
Development	
after	seizure	
onset	
Other	seizure	types	 Age	of	
seizure	
offset	
EEG	 Neuroimaging	 Other	features	 Medications	a	
Individuals	identified	in	this	cohort	T24139	(brother	of	T24629)	 5y	M	 EOEE	Initially	diagnosed	with	hyperekplexia	
C-PAP	ventilation	for	4h	after	birth	 At	birth	(abnormal	movements	in	utero)	
Jittery	movements	at	birth,	myoclonic	seizures	in	NICU	 Regression	at	2y	Severe	ID	 Tonic-clonic	Focal	tonic	Focal	impaired	awareness	CSE	Ongoing	myoclonic	seizures	(spontaneous	and	reflex	to	noise	and	touch)	
Ongoing	 Multifocal	Diffuse	slowing	R	tempoparietal	spikes	 Normal	 Hypertonia	Hyperreflexia	Transient	ventricular	tachycardia	Hyperkeratosis	of	feet	Gum	hypertrophy	(PHT	use)	2	small	café	au	lait	lesions	
LTG,	TPM,	LEV,	PB,	MDZ,	CLZ,	CZP,	PHT,	lignocaine,	pyridoxine,	propranolol,	pyridoxal-phosphate	
T24629	(sister	of	T24139)	 15y	F	 EOEE	Initially	diagnosed	with	hyperekplexia	
Delayed	 5h	(abnormal	movements	in	utero)	
Focal	myoclonic	 Severe	ID	 Tonic-clonic	Focal	CSE	Tonic	
Ongoing	 Multifocal	Beta	activity	R>L	sharp	and	slow	waves	
2d:	suggestive	of	hypoxic	damage	in	periventricular	area	4y:	normal	
Hypertonia	Hyperreflexia	Tremor	Nystagmus	Adducted	thumbs	Gum	hypertrophy	(PHT	use)	Increasing	number	and	size	of	café	au	lait	lesions	over	time	12y:	athetoid	movements	Mannerism:	head	hitting	
LTG,	VPA,	TPM,	LEV,	PB,	CBZ,	CZP,	MDZ,	PHT,	DZP	
T23039	 7y	F	 EOEE	 Normal	until	4mth	 1-2h	 Tonic-clonic	 Severe	ID	 Myoclonic		Focal	CSE	Focal	impaired	awareness	 Ongoing	 GSW	PSW	Mild	slowing	bi-mid	central	frontal	area	
4d:	normal	18mth:	bimesial	temporal	lobe	increased	T2	signal	 Hyperreflexia	Ataxia	Very	active		
VPA,	AZD,	CZP,	PB,	CLB,	TPM,	LTG,	LEV,	ETX	
EG1371	 4y	M	 EIMFS	 Delayed	 4w	 Tonic	with	focal	features	 Severe	ID	 Asymmetric	tonic	Focal	motor	Focal	NCSE	 Ongoing	 Migration	of	rhythmic	left	predominant	2-4	Hz	bi-occipital	activity	to	right	5-6	Hz	theta	activity	L>R	posterior	quadrant	slowing		
2mth:	normal	 Alternating	convergent	strabismus	Cerebral	palsy	 LEV,	STP,	CBZ,	VPA,	TPM,	RFM,	VGB,	ZNS	
EG1519	 12y	F	 EOEE	 Delayed	 1d	 CSE		 Moderate	ID	 2	additional	CSE	at	14mth	and	24mth	without	intervening	seizures	Tonic	with	R	hemifacial	clonic	and	L	eye	deviation		
Ongoing	 Bi-frontal,	L	fronto-central	and	temporal	slowing	 Normal	 Mild	diffuse	hypotonia	Ataxic	gait	Intention	tremor	 TPM,	LTG,	CLB,	VPA,	LEV,	KD	
Individuals	identified	in	Epi,	Epilepsy	Phenome/Genome	et	al.	2013	EPGP011141	 19y	F	 EOEE	à	LGS	 Unremarkable	 1h	 Myoclonic	 Severe	ID	Regression	 Tachypnoeic	episode	Tonic-clonic	Focal	impaired	awareness		CSE	Drop	attacks	Myoclonic	(reflex	to	loud	noise)	Tonic	
Ongoing	 GSW	PSW	Generalised	slowing		
CT	newborn	period:	normal	5w:	normal	SPECT	7y:	areas	of	mildly	decreased	radiopharmaceutical	uptake	in	L	frontal,	parietal	and	temporal	lobes	
Bilateral	alternating	esotropia	Unsustained	nystagmus	on	lateral	gaze	bilaterally	Ataxic	gait	Autism	Generalised	hypotonia	15y:	contractures	
VPA,	VGB,	CLB,	FBM,	CBZ,	GBP,	KD,	LTG,	AZD,	TPM,	VNS,	DZP,	PHT,	PB,	ZNS,	levocarnitine	
ACTH,	adrenocorticotropic	hormone;	ADHD,	attention	deficit	hyperactivity	disorder;	AZD,	acetazolamide;	CBZ,	carbamazepine;	CC,	corpus	callosum;	CLB,	clobazam;	CLZ,	clorazepate;	C-PAP,	continuous	positive	airway	pressure;	CSF,	cerebral	spinal	fluid;	CT,	computed	tomography;	CSE,	convulsive	status	epilepticus;	CZP,	clonazepam;	d,	days;	DZP,	diazepam;	EE,	epileptic	encephalopathy;	EIEE,	early	infantile	epileptic	encephalopathy;	EIMFS,	epilepsy	of	infancy	with	migrating	focal	seizures;	EME,	early	myoclonic	encephalopathy;	EOEE,	early	onset	epileptic	encephalopathy;	ETX,	ethosuxamide;	F,	female;	FBM,	felbamate;	FIAS,	focal	impaired	awareness	seizure;	FS,	febrile	seizures;	GBP,	gabapentin;	GORD,	gastro-oesophageal	reflux	disease;	GPFA,	generalised	paroxysmal	fast	activity;	GSW,	generalised	spike	wave;	h,	hours;	ID,	intellectual	disability;	IS,	infantile	spasms;	KD,	ketogenic	diet;	kg,	kilograms;	L,	left;	LCM,	lacosamide;	LEV,	levetiracetam;	LTG,	lamotrigine;	LGS,	Lennox-Gastaut	Syndrome;	M,	male;	MAD,	modified	Atkins	diet;	MDZ,	midazolam;	mth,	months;	NCSE,	non-convulsive	status	epilepticus;	NG,	nasogastric;	NICU,	neonatal	intensive	care	unit;	NZP,	nitrazepam;	OCBZ,	oxcarbazepine;	PB,	phenobarbitone;	PFA,	paroxysmal	fast	activity;	PHT,	phenytoin;	PRM,	primidone;	PSW,	polyspike	wave;	PEG,	percutaneous	endoscopic	gastrostomy;	R,	right;	RFM,	rufinamide;	sec,	seconds;	SE,	status	epilepticus;	SGE,	symptomatic	generalised	epilepsy;	SPECT,	single-photon	emission	computed	tomography;	STP,	stiripentol;	SSW,	slow	spike	wave;	TPM,	topiramate;	VGB,	vigabatrin;	VNS,	vagus	nerve	stimulation;	VPA,	valproate;	w,	weeks;	y,	years;	ZNS,	zonisamide	a	medications	current	at	last	follow-up	underlined	 	
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